<DOC>
	<DOC>NCT00717145</DOC>
	<brief_summary>Randomized, open-label, multi-center, 4-treatment, 4-period crossover study. The study will consist of a screening visit, study center admission (preceding Treatment Periods 1, 2, 3, and 4), 4 treatment periods (4 days each), 3 washout periods (14 to 17 days in duration separating each treatment period), and exit procedures.</brief_summary>
	<brief_title>Food Effects on the Relative Bioavailability of Different Dosages of Risedronate</brief_title>
	<detailed_description />
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>nonlactating and either surgically sterile or postmenopausal: body mass index less than or equal to 32 kg/m2 at screening No use of a bisphosphonate within 1 month no history of GI disease no use of any medications within 714 days prior to scheduled dosing day</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>bioequivalence</keyword>
</DOC>